Antipsychotic-like properties of phosphodiesterase 4 inhibitors: evaluation of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with auditory event-related potentials and prepulse inhibition of startle

The Journal of Pharmacology and Experimental Therapeutics
Tobias B Halene, Steven J Siegel

Abstract

Antipsychotic medications function through antagonism of D2 dopamine receptors. Blockade of D2 receptors causes an increase in intracellular cAMP, a ubiquitous second messenger. Inhibition of phosphodiesterase (PDE) activity, a family of enzymes that degrade cyclic nucleotides, causes the same effect. The conceptual linkage between dopamine D2 receptors and PDE activity via cAMP suggests a possible therapeutic potential for PDE inhibitors in schizophrenia. The limited number of studies in support of this hypothesis used rolipram, a specific inhibitor of the PDE4 family. In this study, we investigated the impact of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724), another PDE4-specific inhibitor, on auditory event-related potentials (ERPs), prepulse inhibition (PPI) of the startle reflex, and locomotor activity in mice. The ability to reverse amphetamine-induced alterations in ERPs and PPI was used as a model for psychosis. ERPs after RO-20-1724 revealed increased amplitude for the P20 and N40 ERP components. RO-20-1724 reversed the disruptive effect of amphetamines on ERPs and restored gating at a dose that did not impair locomotor activity. However, RO-20-1724 failed to reverse a amphetamine-induced decrease of PPI....Continue Reading

References

Nov 1, 1992·Physiology & Behavior·G E PloegerA R Cools
May 5, 1997·Psychiatry Research·Y JinW E Bunney
Nov 28, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Helen Rosengarten, David Quartermain
Dec 31, 2002·Psychoneuroendocrinology·R Tandon, M D Jibson
Jan 29, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ali Saffet GonulAlpaslan Yilmaz
Mar 26, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Steven J SiegelBruce I Turetsky
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shitij Kapur, David Mamo
Mar 17, 2004·Trends in Pharmacological Sciences·James M O'Donnell, Han-Ting Zhang
Apr 21, 2005·Behavioral Neuroscience·Jennifer A Davis, Thomas J Gould
Aug 27, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Neal R SwerdlowPamela P Auerbach
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Nov 1, 2005·Drug Discovery Today·Miles D HouslayKam Y J Zhang
Nov 23, 2005·Expert Opinion on Therapeutic Targets·Kam Y J ZhangGideon Bollag
May 8, 2007·Neuron·Steven J ClapcoteJohn C Roder
Aug 31, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Hannah MurdochMiles D Houslay
Sep 8, 2007·The Journal of Physiology·J Kirsty MillarDavid J Porteous
Nov 29, 2007·The International Journal of Neuroscience·Satoru NakaiTetsuro Kikuchi

❮ Previous
Next ❯

Citations

Aug 19, 2008·Psychopharmacology·Olga A H ReneerkensJos Prickaerts
Dec 17, 2009·Psychopharmacology·Tatiana Lipina, John Roder
Apr 3, 2013·European Journal of Clinical Pharmacology·Melvin GeorgeSteven Aibor Dkhar
Jul 23, 2013·Neuroscience and Biobehavioral Reviews·Steven J SiegelMark A Geyer
Oct 5, 2011·Proceedings of the National Academy of Sciences of the United States of America·Gregory C CarlsonSteven J Siegel
Apr 17, 2010·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Noam D RudnickSteven J Siegel
Jul 16, 2009·The Journal of Pharmacology and Experimental Therapeutics·Christina L BodarkySteven J Siegel
Jul 9, 2009·Journal of Cognitive Neuroscience·Maciej T LazarewiczSteven J Siegel
Oct 9, 2013·Psychopharmacology·Ana C IssyElaine A Del-Bel
Dec 5, 2013·Physiological Reports·Robert E LinSteven J Siegel
Aug 3, 2012·Psychopharmacology·O A H ReneerkensJ Prickaerts
Dec 24, 2013·Future Medicinal Chemistry·Pawel ZajdelAnna Wesolowska
May 9, 2013·Expert Opinion on Drug Discovery·Kurt Leroy Hoffman
Apr 6, 2011·Pharmacology, Biochemistry, and Behavior·Tanya L WallaceJoseph G Wettstein
May 4, 2010·Brain Research Bulletin·Laura C AmannSteven J Siegel
Jan 6, 2016·Indian Journal of Pharmacology·Vasantmeghna S Murthy, Ajish G Mangot
Apr 1, 2015·Annals of the New York Academy of Sciences·Robert E FeatherstoneSteven J Siegel
Aug 23, 2011·Neuropharmacology·Joshua S RodeferSamuel J Eckrich
May 22, 2013·Behavioural Brain Research·O A H ReneerkensJ Prickaerts
Dec 3, 2014·Neurobiology of Learning and Memory·P R A HeckmanJ Prickaerts
May 11, 2012·Developmental Neuroscience·Neal R SwerdlowSusan B Powell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Auditory Perception

Auditory perception is the ability to receive and interpret information attained by the ears. Here is the latest research on factors and underlying mechanisms that influence auditory perception.